Surgical Management of Giant Prolactinomas: A Descriptive Study

Table 1

Baseline characteristics of patients with giant prolactinoma prior to treatment.

Case no	Age (years)	Gender	Race	Presenting symptoms	Initial PRL (μg/L)	Preoperative central hormone deficit(s)^†	Largest tumor dimension (cm)	Initial tumor volume (cm^3)^†
1	38	Male	White	Headache, weakness, visual deficit, behavior changes	N/A–not evaluated	N/A–not evaluated	5	40.0
2	53	Male	White	Weakness, visual deficit, ophthalmoplegia, behavior changes	3,482	Hypogonadism, hypothyroidism, adrenal insufficiency	7.7	109.3
3	20	Female	Black	Secondary amenorrhea, headache, visual deficit	1,111	Hypogonadism, hypothyroidism, adrenal insufficiency	6	27.3
4	39	Male	Black	Headache, weakness, visual deficit, ophthalmoplegia, behavior changes, low libido	2,498	Hypogonadism	4.6	22.8
5	26	Male	White	Headache, visual deficit, ophthalmoplegia, low libido	686	Hypogonadism	5.9	31.0
6	33	Male	White	Galactorrhea, headache, visual deficit, low libido	>13,000	Hypogonadism	5	30.6
7	47	Male	White	Headache, ophthalmoplegia, behavior change, memory loss	∼100^ǂ	N/A–not evaluated	9	N/A–unavailable
8	51	Female	Black	Visual deficit, low libido	11,477	Hypogonadism	6	46.5

^†Growth hormone deficiency was not tested in any patient. Patient declined preoperative blood evaluation. ^ǂExact value unavailable, serial dilution was not performed, falsely low prolactin level was consistent with hook effect. ^†Tumor volume calculated using geometric formula, volume = ½ (). PRL (prolactin).